Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Non-Current Deffered Revenue (2021 - 2025)

Zymeworks' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $32.9 million for Q3 2023.

  • For Q3 2023, Non-Current Deffered Revenue changed 0.0% year-over-year to $32.9 million; the TTM value through Sep 2023 reached $32.9 million, changed 0.0%, while the annual FY2022 figure was $30.6 million, 7.14% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2023 was $32.9 million at Zymeworks, up from $30.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $32.9 million in Q4 2021 and bottomed at $30.6 million in Q4 2022.
  • The 3-year median for Non-Current Deffered Revenue is $31.8 million (2021), against an average of $31.8 million.
  • The largest annual shift saw Non-Current Deffered Revenue dropped 7.14% in 2022 before it changed 0.0% in 2023.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $32.9 million in 2021, then dropped by 7.14% to $30.6 million in 2022, then increased by 7.69% to $32.9 million in 2023.
  • Per Business Quant, the three most recent readings for ZYME's Non-Current Deffered Revenue are $32.9 million (Q3 2023), $30.6 million (Q2 2023), and $30.6 million (Q1 2023).